Choice of control group in randomised trials of cancer medicine: are we testing trivialities?

Lancet Oncol. 2018 Sep;19(9):1150-1152. doi: 10.1016/S1470-2045(18)30501-1.

Authors

Derrick Tao¹, Vinay Prasad²

Affiliations

¹ Department of Medicine, Oregon Health & Science University, Portland, OR, USA.
² Division of Hematology Oncology, Knight Cancer Institute, Department of Public Health and Preventive Medicine, and Center for Health Care Ethics, Oregon Health & Science University, Portland, OR 97239, USA. Electronic address: [email protected].

PMID: 30191836
DOI: 10.1016/S1470-2045(18)30501-1

No abstract available

MeSH terms

Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Drug Approval*
Evidence-Based Medicine / methods*
Evidence-Based Medicine / standards
Humans
Neoplasms / diagnosis
Neoplasms / drug therapy*
Neoplasms / mortality
Randomized Controlled Trials as Topic / methods*
Randomized Controlled Trials as Topic / standards
Research Design* / standards
Treatment Outcome

Substances

Antineoplastic Agents